Submit Manuscript

International Journal of Cancer Research

Year: 2005 | Volume: 1 | Issue: 1 | Page No.: 5-9
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend

Total views 62

Authors

Magdy Sayed Aly

Keywords

Research Article

HER-2/neu Gene Amplification in Prostate Cancer from Egyptian Patients by Fluorescence in situ Hybridization

Magdy Sayed Aly
Prostate cancer is the most frequent malignancy and the second leading cause of cancer deaths among males in the Western world. A study of 40 cases of prostate cancer is conducted in an attempt to identify prognostic biomarkers that can distinguish aggressive cases that must be treated immediately. HER-2/neu oncogene amplification was initially studied because amplification of this gene has been reported in many other types of cancer. In this study, HER-2 gene amplification was assessed by fluorescence in situ hybridization (FISH) using a HER-2/neu gene probe with a chromosome 17 centromere control probe. The study was performed on formalin-fixed, paraffin-embedded tissues. FISH successfully analyzed all cases. Only 5 out of 40 (12.5%) were found to be amplified. This frequency was lower than the frequency of amplification found in other in other cancers studied. The level of amplification observed was correlated with the pathological grade. Our data indicate that HER-2/neu gene amplification status can be determined by FISH on archival prostate cancer specimens, significantly correlates with high tumor grade and is more frequently encountered in tumors with advanced pathological stage. Also, FISH is a sensitive technique for detection of abnormalities in the HER-2/neu gene and further studies should be undertaken to determine whether a FISH-based HER-2/neu detection method may prove of importance in the prediction of prognosis and planning of therapy in prostate cancer patients.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *